IBDEI0JE ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8726,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,8726,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,8726,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,8727,0)
 ;;=Z85.528^^39^402^83
 ;;^UTILITY(U,$J,358.3,8727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8727,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,8727,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,8727,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,8728,0)
 ;;=Z85.6^^39^402^74
 ;;^UTILITY(U,$J,358.3,8728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8728,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,8728,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,8728,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,8729,0)
 ;;=Z85.72^^39^402^98
 ;;^UTILITY(U,$J,358.3,8729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8729,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,8729,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,8729,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,8730,0)
 ;;=Z85.79^^39^402^88
 ;;^UTILITY(U,$J,358.3,8730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8730,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,8730,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,8730,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,8731,0)
 ;;=Z85.820^^39^402^77
 ;;^UTILITY(U,$J,358.3,8731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8731,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,8731,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,8731,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,8732,0)
 ;;=Z85.828^^39^402^92
 ;;^UTILITY(U,$J,358.3,8732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8732,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,8732,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,8732,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,8733,0)
 ;;=Z85.71^^39^402^72
 ;;^UTILITY(U,$J,358.3,8733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8733,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,8733,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,8733,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,8734,0)
 ;;=Z65.8^^39^402^144
 ;;^UTILITY(U,$J,358.3,8734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8734,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,8734,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,8734,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,8735,0)
 ;;=Z86.11^^39^402^109
 ;;^UTILITY(U,$J,358.3,8735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8735,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,8735,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,8735,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,8736,0)
 ;;=Z86.13^^39^402^76
 ;;^UTILITY(U,$J,358.3,8736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8736,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,8736,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,8736,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,8737,0)
 ;;=Z86.73^^39^402^106
 ;;^UTILITY(U,$J,358.3,8737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8737,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,8737,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,8737,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,8738,0)
 ;;=Z86.79^^39^402^69
 ;;^UTILITY(U,$J,358.3,8738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8738,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
